Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation
Status: Enrolling
Updated:  5/30/2014
Washington University
mi
from
St. Louis, MO
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation
Status: Enrolling
Updated: 5/30/2014
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation
Status: Enrolling
Updated:  5/30/2014
Cincinnati Children's Hospital in partnership with University Hospital of Cincinnati
mi
from
Cincinnati, OH
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation
Status: Enrolling
Updated: 5/30/2014
Cincinnati Children's Hospital in partnership with University Hospital of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation
Status: Enrolling
Updated:  5/30/2014
University of Virginia
mi
from
Charlottesville, VA
MagniXene MRI Use in Patients With Asthma and COPD to Assess Regional Lung Function by Delineating Ventilation Defects
Study of Hyperpolarized Xenon (MagniXene) in Patients With Obstructive Pulmonary Diseases (Asthma and COPD) to Assess Regional Lung Function by Delineating Regions of Abnormal Lung Ventilation
Status: Enrolling
Updated: 5/30/2014
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Randomized, Crossover Safety and Pharmacokinetics Study of PT010
A Phase I, Randomized, Double Blind, Placebo-Controlled, Two Period, Ascending Dose, Crossover Study to Assess the Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days
Status: Enrolling
Updated:  7/22/2014
SNBL Clinical Pharmacology Center
mi
from
Baltimore, MD
Randomized, Crossover Safety and Pharmacokinetics Study of PT010
A Phase I, Randomized, Double Blind, Placebo-Controlled, Two Period, Ascending Dose, Crossover Study to Assess the Safety and Pharmacokinetics of Two Doses of PT010 in Healthy Adult Subjects of Japanese Descent Following a Single Dose and After Chronic Dosing for 7 Days
Status: Enrolling
Updated: 7/22/2014
SNBL Clinical Pharmacology Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
Advanced Pharma CR, LLC
mi
from
Miami, FL
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
Advanced Pharma CR, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
Elite Research Institute
mi
from
Miami, FL
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
Elite Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
Compass Research LLC
mi
from
Orlando, FL
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
Compass Research LLC
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
University at Buffalo CTRC
mi
from
Buffalo, NY
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
University at Buffalo CTRC
mi
from
Buffalo, NY
Click here to add this to my saved trials
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated:  8/13/2014
Volunteer Research Group
mi
from
Knoxville, TN
Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Chronic Obstructive Pulmonary Disease
Status: Enrolling
Updated: 8/13/2014
Volunteer Research Group
mi
from
Knoxville, TN
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Torrance, CA
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Torrance, CA
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Waterbury, CT
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Waterbury, CT
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Savannah, GA
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Savannah, GA
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Normal, IL
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Normal, IL
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Missoula, MT
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Missoula, MT
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Cincinnati, OH
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Columbus, OH
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Columbus, OH
Click here to add this to my saved trials
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated:  8/26/2014
Novartis Investigative Site
mi
from
Spartanburg, SC
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
A Randomized, Double Blind, Placebo Controlled, Multi-centre Study to Asses the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of BYM338 in Chronic Obstructive Pulmonary Disease Patients With Cachexia
Status: Enrolling
Updated: 8/26/2014
Novartis Investigative Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Efficacy and Safety of AQX-1125 in Unstable COPD
The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway
Status: Enrolling
Updated:  10/23/2014
University of Cincinnati
mi
from
Cincinnati, OH
Efficacy and Safety of AQX-1125 in Unstable COPD
The FLAGSHIP Study: A 12-week Phase II Study to Evaluate the Efficacy and Safety of AQX-1125 Following Exacerbations in Patients With Chronic Obstructive Pulmonary Disease (COPD) by Targeting the SHIP1 Pathway
Status: Enrolling
Updated: 10/23/2014
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Status: Enrolling
Updated:  10/31/2014
Dayton VA Medical Center
mi
from
Dayton, OH
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Status: Enrolling
Updated: 10/31/2014
Dayton VA Medical Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Status: Enrolling
Updated:  10/31/2014
Dayton VA Medical Center
mi
from
Dayton, OH
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Sedation and Physiological Effects of Intranasal Dexmedetomidine in Severe COPD
Status: Enrolling
Updated: 10/31/2014
Dayton VA Medical Center
mi
from
Dayton, OH
Click here to add this to my saved trials
Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model
Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model
Status: Enrolling
Updated:  12/8/2014
Moses Taylor Hospital
mi
from
Scranton, PA
Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model
Improving Medication Adherence Through a Transitional Care Pharmacy Practice Model
Status: Enrolling
Updated: 12/8/2014
Moses Taylor Hospital
mi
from
Scranton, PA
Click here to add this to my saved trials
Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke
Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke
Status: Enrolling
Updated:  1/13/2015
Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine
mi
from
New York, NY
Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke
Modulation of Genes Responsible for Cilia Length by Exposure to Cigarette Smoke
Status: Enrolling
Updated: 1/13/2015
Weill Cornell Medical College and Weill Cornell Medical Center, Department of Genetic Medicine
mi
from
New York, NY
Click here to add this to my saved trials
To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions
A Randomised Placebo-controlled Study to Evaluate the Effects of GSK2256294 Following Repeat Dosing on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions
Status: Enrolling
Updated:  1/15/2015
GSK Investigational Site
mi
from
Baltimore, MD
To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions
A Randomised Placebo-controlled Study to Evaluate the Effects of GSK2256294 Following Repeat Dosing on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions
Status: Enrolling
Updated: 1/15/2015
GSK Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Respiratory Disease Management
Use of a Respiratory Care Practitioner Disease Management (RCP-DM) Program for Patients Hospitalized With COPD
Status: Enrolling
Updated:  1/26/2015
Barnes Jewish Hospital
mi
from
St. Louis, MO
Respiratory Disease Management
Use of a Respiratory Care Practitioner Disease Management (RCP-DM) Program for Patients Hospitalized With COPD
Status: Enrolling
Updated: 1/26/2015
Barnes Jewish Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
Economic and Humanistic Impact of Low Peak Inspiratory Flow Rate (PIFR) In COPD Patients: An Observational Analysis
Economic and Humanistic Impact of Low Peak Inspiratory Flow Rate (PIFR) In COPD Patients: An Observational Analysis
Status: Enrolling
Updated:  4/3/2015
EPI-Q
mi
from
Oak Brook, IL
Economic and Humanistic Impact of Low Peak Inspiratory Flow Rate (PIFR) In COPD Patients: An Observational Analysis
Economic and Humanistic Impact of Low Peak Inspiratory Flow Rate (PIFR) In COPD Patients: An Observational Analysis
Status: Enrolling
Updated: 4/3/2015
EPI-Q
mi
from
Oak Brook, IL
Click here to add this to my saved trials
A Registry of COPD Patients to be Used for Future Studies
The Ohio State University COPD Registry
Status: Enrolling
Updated:  4/20/2015
Ohio State University
mi
from
Columbus, OH
A Registry of COPD Patients to be Used for Future Studies
The Ohio State University COPD Registry
Status: Enrolling
Updated: 4/20/2015
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients
Status: Enrolling
Updated:  5/18/2015
Baylor College of Medicine
mi
from
Houston, TX
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients
Detecting Errors In Using Metered Dose Inhalers (MDI) Among Asthma And COPD Patients
Status: Enrolling
Updated: 5/18/2015
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Monitoring Chronic Obstructive Pulmonary Disease Patients at Home by a Forced Oscillation Technique Device
Monitoring COPD Patients at Home by a Forced Oscillation Technique Device
Status: Enrolling
Updated:  6/2/2015
Baylor College of Medicine
mi
from
Houston, Texas, TX
Monitoring Chronic Obstructive Pulmonary Disease Patients at Home by a Forced Oscillation Technique Device
Monitoring COPD Patients at Home by a Forced Oscillation Technique Device
Status: Enrolling
Updated: 6/2/2015
Baylor College of Medicine
mi
from
Houston, Texas, TX
Click here to add this to my saved trials
Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity
Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity
Status: Enrolling
Updated:  7/2/2015
Columbia University Cardiopulmonary, Sleep and Ventilatory Disorders Center
mi
from
NY, NY
Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity
Single-Breath Measurement Underestimates Ventilatory Volume According to Emphysema Severity
Status: Enrolling
Updated: 7/2/2015
Columbia University Cardiopulmonary, Sleep and Ventilatory Disorders Center
mi
from
NY, NY
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Andalusia, AL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Andalusia, AL
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Anniston, AL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Anniston, AL
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Athens, AL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Athens, AL
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Birmingham, AL
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Mesa, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Mesa, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Phoenix, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Phoenix, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Scottsdale, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Tucson, AZ
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Anaheim, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Anaheim, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Carlsbad, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Carlsbad, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Lakewood, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Lakewood, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Los Angeles, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Pasadena, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Pasadena, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Pasedena, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Pasedena, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Poway, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Poway, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Sacramento, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Sacramento, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
San Diego, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Tustin, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Tustin, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Vista, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Vista, CA
Click here to add this to my saved trials
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated:  7/7/2015
Pearl Investigative Site
mi
from
Vista, CA
Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)
A Randomized, Double Blind, Chronic Dosing, Placebo-Controlled, Parallel Group, Multi Center Study to Assess the Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe COPD, Compared With Placebo and Spiriva® Handihaler® (Tiotropium Bromide 18 µg Open-Label) as an Active Control
Status: Enrolling
Updated: 7/7/2015
Pearl Investigative Site
mi
from
Vista, CA
Click here to add this to my saved trials